Abstract
We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Bronchoalveolar Lavage Fluid
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Humans
-
Lymphoma, B-Cell / complications*
-
Lymphoma, B-Cell / drug therapy
-
Microscopy, Fluorescence
-
Middle Aged
-
Pneumocystis / metabolism*
-
Pneumonia, Pneumocystis / complications*
-
Pneumonia, Pneumocystis / drug therapy
-
Polymerase Chain Reaction
-
Prednisone / administration & dosage
-
Rituximab
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone